达努格利的分子对接揭示了GLP-1R与内分泌系统之间的潜在交叉
Kiersten A Dailey1, Lillian N Schneider1, Ruben C Petreaca2
1Biology program, The Ohio State University at Marion, Marion, Ohio, United States.
microPublication biology
|August 21, 2025
概括
针对GLP-1R的减肥药可能与大麻素受体相互作用. 分子对接显示danuglipron与CB1和CB2强烈结合,表明这些系统之间的潜在交叉反应.
科学领域:
- 药理学
- 神经科学
- 分子生物学
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 激动剂是常见的减肥药物.
- 大麻素如delta-9-tetrahydrocannabinol (THC) 与内分泌系统的CB1和CB2受体相互作用.
- GLP-1R和大麻素受体都是G蛋白结合受体 (GPCR).
研究的目的:
- 调查内分泌系统和GLP-1R系统之间的潜在相互作用.
- 探索GLP-1R激动剂与大麻素受体之间的交叉反应.
主要方法:
- 使用分子对接实验.
- 测试了内源性 (2-AG,安纳米德) 和外源性 (THC) 内类大麻素配体.
- 评估了一种小口服GLP-1R激动剂,达努格利.
主要成果:
- 达努格利对CB1和CB2受体具有较高的结合亲和力.
- 这种GLP-1R激活剂与大麻素受体具有潜在的交叉反应性.
结论:
- 这些发现表明GLP-1R与内分泌系统之间存在潜在的重叠.
- 需要进一步的研究来探索这种交叉反应的含义.
更多相关视频
08:49Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
Published on: June 20, 2025
523
11:06Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
Published on: April 7, 2023
2.2K
相关概念视频
Glucagon-like Receptor Agonists
416
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
416
Dipeptidyl Peptidase 4 Inhibitors
256
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
256
G Protein-coupled Receptors
13.3K
G Protein-Coupled Receptors or GPCRs are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to sensory stimuli such as light, odors, hormones, cytokines, or neurotransmitters.
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
13.3K
Oral Hypoglycemic Agents: Glinides
257
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
257
GPCRs Regulate Adenylyl Cylase Activity
5.9K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.9K
Drug-Receptor Interaction: Agonist
2.8K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.8K
